Value through Innovation01 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

01.06.2013

Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study

- For non U.S. Media Only
28.05.2013

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

- Not intended for media in the UK, the US or Canada
24.05.2013

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

- For Non-U.S. and Non-UK media
22.05.2013

Boehringer Ingelheim responds to FDA warning letter

22.05.2013

Wireless Pill Bottle Wins Healthcare Innovation World Cup

21.05.2013

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

- For Media outside the U.S., Canada and UK
17.05.2013

Change in the Board of Managing Directors at Boehringer Ingelheim

16.05.2013

ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

16.05.2013

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

- For non U.S. Media Only
06.05.2013

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases

25.04.2013

Boehringer Ingelheim Announces a Strong 2012 Performance in China

24.04.2013

Boehringer Ingelheim consistently continues growth phase in financial year 2012

23.04.2013

Boehringer Ingelheim announces results from one of its HCV Phase III trials:
Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1
hepatitis C

- For media outside USA, UK and Canada only
02.04.2013

Innovative treatment for canine epilepsy: European approval granted for Boehringer Ingelheim’s Pexion®

26.03.2013

FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)

- For media outside of the US, the UK & Canada only
26.03.2013

Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*

- EX US & UK Medical Media Only
19.03.2013

Boehringer Ingelheim and Lilly initiate MARLINA-T2D™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria

- For Non-U.S. and Non-U.K. Media
18.03.2013

Boehringer Ingelheim Animal Health sponsors PCV2 research projects with more than 400,000 euro